Author of

• 12727

  +

  P3.13 - Poster Session 3 - SCLC (ID 202)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12730

    +

    P3.13-003 - Survival of patients with small cell lung carcinoma in Taiwan (ID 1252)

    09:30 - 09:30  |  Author(s): Y. Yang
    • Abstract

    Background
    Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. The prognosis for SCLC patients remains unsatisfactory, despite advances in chemotherapy. In this study, we sought to clarify the prognosis and treatment patterns of patients with SCLC.

    Methods
    A cohort comprising all patients diagnosed with SCLC between Jan. 2004 and Dec. 2006 was assembled from the Taiwan Cancer Database. Patients were followed up until December 31, 2009 to determine overall survival. Patient survival was estimated using the Kaplan-Meier method, and Cox’s proportional hazard model was used to determine the relationship between prognostic factors and median survival time.

    Results
    Among the 1684 patients diagnosed with SCLC, 1215 (72%) were diagnosed with extensive stage, and 469 (28%) with limited stage. Most of the patients were male (90%). The median survival time of patients with limited-stage (LS) and extensive-stage (ES) SCLC was 10.3 months and 5.6 months, respectively. For LS patients, surgery, chemotherapy, and combined chemotherapy and radiotherapy resulted in better survival than best supportive care (HR: 0.20, p<0.001; HR: 0.61, p<0.001; HR: 0.37, p<0.001 respectively). For ES patients, male gender was significantly associated with poor prognosis (HR:1.45, p<0.001) and chemotherapy was shown to improve overall survival more effectively than best supportive care (HR: 0.37, p<0.001).

    Conclusion
    For LS SCLC patients, surgery, chemotherapy, and combined chemotherapy and radiotherapy improved survival compared to best supportive care. ES SCLC patients benefited more from chemotherapy treatment than best supportive care.